Keyphrases
Breast Cancer Susceptibility Gene 1 (BRCA1)
63%
BRCA2
46%
Breast Cancer
46%
Breast Cancer Risk
45%
BRCA2 mutation
42%
Tumor
41%
BRCA1, BRCA2
39%
Denmark
39%
Ovarian Cancer Risk
36%
Germ Cells
33%
Pathogenic Variants
32%
Ovarian Cancer
32%
BRCA mutation Carriers
31%
MicroRNA
30%
Pseudomonas Aeruginosa (P. aeruginosa)
27%
Gene Expression
27%
Whole Genome Sequencing
25%
Cystic Fibrosis
25%
High-risk Human Papillomavirus (HR-HPV)
23%
Circulating Tumor DNA (ctDNA)
23%
Next-generation Sequencing
18%
Genome-wide Association Study
18%
Confidence Interval
16%
Variants of Uncertain Significance
15%
Hazard Ratio
15%
Overall Survival
14%
Copenhagen
14%
Alpha-mannosidosis
14%
Mutation Carriers
13%
Whole Exome Sequencing
13%
Transcriptome
13%
Genetic Modification
13%
Multiple Endocrine Neoplasia Type 2 (MEN2)
13%
Rearranged during Transfection
13%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
13%
Susceptibility Loci
12%
Genotype
12%
Medullary Thyroid Carcinoma
12%
Glioblastoma
12%
Single nucleotide Polymorphism
12%
Genetic Variants
12%
Missense Variants
12%
Cancer Risk
11%
Velmanase Alfa
11%
Quantitative PCR
10%
Cell-free DNA (cfDNA)
10%
Breast Cancer Patients
10%
Epithelial Ovarian Cancer
10%
Copy number Variation
10%
High Risk
10%
Germline Variants
10%
In Cancer
10%
Targeted Treatment
9%
Metastasis
9%
Genetic Screening
9%
Molecular Subtypes
9%
Colorectal Cancer
9%
Microarray
9%
SNP
9%
Germline mutation
9%
Pathogenic Germline Variant
8%
Breast
8%
Genome Sequencing
8%
Polygenic Risk Score
8%
Genetic Testing
8%
Odds Ratio
8%
Granulosa Cells
8%
Thrombocytopenia
8%
BRCA mutation
8%
RNA Sequencing (RNA-seq)
8%
Head-and-neck Cancer
8%
Targeted Therapy
8%
Airway
8%
Proband
8%
Population-based Study
8%
Immunohistochemistry
7%
Antibiotic Resistance
7%
Single-cell RNA Sequencing (scRNA-seq)
7%
Primary Hyperparathyroidism (pHPT)
7%
Multiple Endocrine Neoplasia Type 1 (MEN1)
7%
Sequence Data
7%
Protein Language Model
7%
Clinical Impact
7%
Metastatic Melanoma
7%
Primary Tumor
7%
Danish Population
7%
Clinically Significant
7%
Tumor Protein p53 (TP53)
7%
Tumor Growth
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
7%
Molecular Profiling
7%
Endolymphatic Sac
7%
Sinonasal Intestinal-type Adenocarcinoma
7%
Clinical Characterization
7%
In Silico
7%
Clinical Outcomes
7%
Pheochromocytoma
7%
Splicing Analysis
6%
Platelets
6%
Signaling Pathway
6%
Biochemistry, Genetics and Molecular Biology
BRCA1
100%
BRCA2
77%
Germ Cell
58%
Germline
58%
Genetics
47%
MicroRNA
27%
Next Generation Sequencing
26%
Allele
26%
Gene Expression
24%
Transcriptome
23%
Whole Genome Sequencing
22%
Pseudomonas aeruginosa
22%
Overall Survival
21%
Genetic Divergence
21%
Messenger RNA
21%
RNA
20%
Estrogen Receptor
20%
Genotyping
18%
Genome-Wide Association Study
18%
Cystic Fibrosis
17%
RNA Sequence
16%
Gene Expression Profiling
16%
Exome Sequencing
15%
Wart Virus
14%
Genomics
14%
Missense
13%
T Cell
13%
Microarrays
13%
Transfection
12%
Exon
12%
Single-Nucleotide Polymorphism
12%
Platelet
12%
Circulating Tumor DNA
12%
Genetic Screening
11%
Single Nucleotide Polymorphism
11%
Computer Model
10%
Thrombocytopenia
10%
RNA Splicing
10%
Homologous Recombination
10%
Gene Mutation
10%
Tumor Suppressor Gene
10%
Prevalence
9%
Clinical Trial
9%
Ovulation
9%
Subcellular Localization
9%
DNA Repair
9%
Subtyping
8%
Transcription Factors
8%
Progression Free Survival
8%
Infectious Agent
8%
Downregulation
8%
Dynamics
8%
Proband
8%
Transcriptomics
7%
Wild Type
7%
DNA Mismatch Repair
7%
Mouse
7%
Genome Sequencing
7%
DNA Methylation
7%
Alpha-Mannosidosis
7%
Mannosidosis
7%
Exome
7%
Deep Sequencing
7%
Cohort Study
7%
B Cell
6%
Epidermal Growth Factor Receptor
6%
Population
6%
Germline Mutation
6%
Antibiotic Resistance
6%
Myeloid
6%
Oncogene
6%
Human Immunodeficiency Virus 1
5%
Human Chorionic Gonadotropin
5%
Eicosanoid Receptor
5%
Cancer Cell
5%
Penetrance
5%
Human Papillomavirus Type 16
5%
SDHB
5%
Binding Site
5%
Polymerase Chain Reaction
5%
Flow Cytometry
5%
Real-Time Polymerase Chain Reaction
5%
P16
5%
Signal Transduction
5%
Enzyme
5%
Medicine and Dentistry
Neoplasm
61%
Breast Cancer
55%
BRCA1
40%
Ovarian Cancer
39%
Malignant Neoplasm
38%
BRCA2
32%
Cancer Risk
29%
Disease
26%
Diagnosis
25%
Wart Virus
23%
Gene Expression
19%
microRNA
16%
Next Generation Sequencing
15%
Overall Survival
15%
Circulating Tumor DNA
14%
Targeted Therapy
14%
Whole Genome Sequencing
13%
Hazard Ratio
12%
Metastatic Carcinoma
12%
Glioblastoma
12%
Estrogen Receptor
11%
Clinical Trial
10%
Prevalence
10%
Biological Marker
10%
Primary Tumor
10%
Exome Sequencing
10%
Adenocarcinoma
10%
Krukenberg Tumor
10%
Oropharynx Squamous Cell Carcinoma
9%
Cell-Free DNA
9%
Colorectal Carcinoma
9%
Platelet
9%
Thrombocytopenia
8%
Mannosidosis
8%
Nodular Melanoma
8%
Single Nucleotide Polymorphism
8%
Thyroid Medullary Carcinoma
8%
In Vitro
8%
Germ Cell
8%
Genetic Screening
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Pediatrics
8%
Oncology
8%
Genome Wide Association Study
8%
T Cell
8%
Immunohistochemistry
7%
Transcriptome
7%
Allele
7%
Primary Hyperparathyroidism
7%
Cancer Susceptibility
7%
Morphology
7%
Non Small Cell Lung Cancer
7%
Oropharyngeal Cancer
7%
Gene Mutation
7%
Liquid Biopsy
6%
Infection
6%
Colorectal Cancer
6%
Biopsy
6%
Genetic Variability
6%
Polyposis
6%
Somatics
6%
Squamous Cell Carcinoma
6%
RNA Sequence
6%
Velmanase Alfa
6%
Gene Expression Profiling
5%
Cystic Fibrosis
5%
Molecular Profiling
5%
Prospective Study
5%
Immunotherapy
5%
In Silico
5%
Cancer Therapy
5%
Mouth Squamous Cell Carcinoma
5%
Head and Neck Cancer
5%
Ovulation
5%
Multiple Endocrine Neoplasia Type I
5%
Bleeding Disorder
5%
Leukemia
5%
Cancer Diagnosis
5%
Endolymphatic Sac
5%
Von Hippel-Lindau Disease
5%
Metastatic Breast Cancer
5%
Randomized Controlled Trial
5%
P16
5%
Acute Myeloid Leukemia
5%
Exon
5%
Personalized Medicine
5%